A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Malignant Neoplasm

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Siqing Fu, MD,PhD)
  • NEXT Oncology, San Antonio, Texas, United States

    Contact: Study coordinator (David Sommerhalder, MD)
  • NEXT Virginia, Fairfax, Virginia, United States

    Contact: Study coordinator (Alexander Spira, MD)
  • Anhui Provincial Cancer Hospital, Hefei, Anhui, China

    Contact: Study coordinator (Yueyin Pan)
    Contact: Principal Investigator (Yueyin Pan)
  • Beijing Cancer Hospital, Beijing, Beijing Municipality, China

    Contact: Study coordinator (Minglei Zhuo)
    Contact: Principal Investigator (Minglei Zhuo)
  • The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

    Contact: Study coordinator (Chengzhi Zhou)
    Contact: Principal Investigator (Chengzhi Zhou)
  • Hubei Cancer Hospital, Wuhan, Hubei, China

    Contact: Study coordinator (Bin Yang)
    Contact: Principal Investigator (Bin Yang)
  • Hunan Cancer Hospital, Changsha, Hunan, China

    Contact: Study coordinator (Lin Wu, MD)
    Contact: Principal Investigator (Lin Wu)
  • The First Affiliated Hospital of Nanchang University - Donghu District, Nanchang, Jiang, China

    Contact: Study coordinator (Yong Li)
    Contact: Study coordinator (Pu Li)
    Contact: Principal Investigator (Yong Li)
    Contact: Principal Investigator (Pu Li)
  • Linyi Cancer Hospital, Linyi, Shandong, China

    Contact: Study coordinator (Janhua Shi)
    Contact: Principal Investigator (Jianhua Shi)
  • Shanghai Tenth People's Hospital, Shanghai, Shanghai Municipality, China

    Contact: Study coordinator (Xiaojun Chen)
    Contact: Principal Investigator (Xiaojun Chen)
  • West China Hospital, Sichuan University, Chengdu, Sichuan, China

    Contact: Study coordinator (Ma Ji)
    Contact: Principal Investigator (Ji Ma)
  • Sir Run Run Shaw Hospital - Zhejiang University School of Med, Hangzhou, Zhejiang, China

    Contact: Study coordinator (Haizhou Lou)
    Contact: Principal Investigator (Haizhou Lou)
  • The First Affiliated Hospital - Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

    Contact: Study coordinator (Jianya Zhou)
    Contact: Principal Investigator (Jianya Zhou)
  • The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

    Contact: Study coordinator (Yuan Ying)
    Contact: Principal Investigator (Ying Yuan)
  • Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang, China

    Contact: Study coordinator (Dongqing Lv)
    Contact: Principal Investigator (Dongqing Lv)
  • Beijing Cancer Hospital, Beijing, China, Beijing, China

    Contact: Study coordinator (Lin Shen)
    Contact: Principal Investigator (Lin Shen, MD)
  • Shanghai Chest Hospital, Shanghai, China, Shanghai, China

    Contact: Study coordinator (Shun Lu)
    Contact: Principal Investigator (Shun Lu, MD)
  • Shanghai Zhongshan Hospital, Shanghai, China, Shanghai, China

    Contact: Study coordinator (Tianshu Liu)
    Contact: Principal Investigator (Tianshu Liu, MD)
מובילי המחקר
  • Cindy Li

    Study Director

    Tyligand Bioscience (Shanghai) Limited